BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24606315)

  • 21. Characterization of the Platelet Phenotype Caused by a Germline RUNX1 Variant in a CRISPR/Cas9-Generated Murine Model.
    Marín-Quílez A; García-Tuñón I; Fernández-Infante C; Hernández-Cano L; Palma-Barqueros V; Vuelta E; Sánchez-Martín M; González-Porras JR; Guerrero C; Benito R; Rivera J; Hernández-Rivas JM; Bastida JM
    Thromb Haemost; 2021 Sep; 121(9):1193-1205. PubMed ID: 33626581
    [No Abstract]   [Full Text] [Related]  

  • 22. Platelet transcriptome analysis in patients with germline RUNX1 mutations.
    Palma-Barqueros V; Bastida JM; López Andreo MJ; Zámora-Cánovas A; Zaninetti C; Ruiz-Pividal JF; Bohdan N; Padilla J; Teruel-Montoya R; Marín-Quilez A; Revilla N; Sánchez-Fuentes A; Rodriguez-Alen A; Benito R; Vicente V; Iturbe T; Greinacher A; Lozano ML; Rivera J; ;
    J Thromb Haemost; 2023 May; 21(5):1352-1365. PubMed ID: 36736831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular phenotype and bleeding risks of an inherited platelet disorder in a family with a RUNX1 frameshift mutation.
    Badin MS; Iyer JK; Chong M; Graf L; Rivard GE; Waye JS; Paterson AD; Pare G; Hayward CPM
    Haemophilia; 2017 May; 23(3):e204-e213. PubMed ID: 28181366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.
    Song WJ; Sullivan MG; Legare RD; Hutchings S; Tan X; Kufrin D; Ratajczak J; Resende IC; Haworth C; Hock R; Loh M; Felix C; Roy DC; Busque L; Kurnit D; Willman C; Gewirtz AM; Speck NA; Bushweller JH; Li FP; Gardiner K; Poncz M; Maris JM; Gilliland DG
    Nat Genet; 1999 Oct; 23(2):166-75. PubMed ID: 10508512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0.
    Manchev VT; Bouzid H; Antony-Debré I; Leite B; Meurice G; Droin N; Prebet T; Costello RT; Vainchenker W; Plo I; Diop M; Macintyre E; Asnafi V; Favier R; Baccini V; Raslova H
    J Cell Mol Med; 2017 Jun; 21(6):1237-1242. PubMed ID: 27997762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrative analysis of RUNX1 downstream pathways and target genes.
    Michaud J; Simpson KM; Escher R; Buchet-Poyau K; Beissbarth T; Carmichael C; Ritchie ME; Schütz F; Cannon P; Liu M; Shen X; Ito Y; Raskind WH; Horwitz MS; Osato M; Turner DR; Speed TP; Kavallaris M; Smyth GK; Scott HS
    BMC Genomics; 2008 Jul; 9():363. PubMed ID: 18671852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects.
    Connelly JP; Kwon EM; Gao Y; Trivedi NS; Elkahloun AG; Horwitz MS; Cheng L; Liu PP
    Blood; 2014 Sep; 124(12):1926-30. PubMed ID: 25114263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrent CDC25C mutations drive malignant transformation in FPD/AML.
    Yoshimi A; Toya T; Kawazu M; Ueno T; Tsukamoto A; Iizuka H; Nakagawa M; Nannya Y; Arai S; Harada H; Usuki K; Hayashi Y; Ito E; Kirito K; Nakajima H; Ichikawa M; Mano H; Kurokawa M
    Nat Commun; 2014 Aug; 5():4770. PubMed ID: 25159113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deletion of RUNX1 exons 1 and 2 associated with familial platelet disorder with propensity to acute myeloid leukemia.
    Cavalcante de Andrade Silva M; Krepischi ACV; Kulikowski LD; Zanardo EA; Nardinelli L; Leal AM; Costa SS; Muto NH; Rocha V; Velloso EDRP
    Cancer Genet; 2018 Apr; 222-223():32-37. PubMed ID: 29666006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of hairy cell leukemia in familial platelet disorder with predisposition to acute myeloid leukemia.
    Toya T; Yoshimi A; Morioka T; Arai S; Ichikawa M; Usuki K; Kurokawa M
    Platelets; 2014; 25(4):300-2. PubMed ID: 23971860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.
    Antony-Debré I; Bluteau D; Itzykson R; Baccini V; Renneville A; Boehlen F; Morabito M; Droin N; Deswarte C; Chang Y; Leverger G; Solary E; Vainchenker W; Favier R; Raslova H
    Blood; 2012 Sep; 120(13):2719-22. PubMed ID: 22677128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML.
    Brown AL; Arts P; Carmichael CL; Babic M; Dobbins J; Chong CE; Schreiber AW; Feng J; Phillips K; Wang PPS; Ha T; Homan CC; King-Smith SL; Rawlings L; Vakulin C; Dubowsky A; Burdett J; Moore S; McKavanagh G; Henry D; Wells A; Mercorella B; Nicola M; Suttle J; Wilkins E; Li XC; Michaud J; Brautigan P; Cannon P; Altree M; Jaensch L; Fine M; Butcher C; D'Andrea RJ; Lewis ID; Hiwase DK; Papaemmanuil E; Horwitz MS; Natsoulis G; Rienhoff HY; Patton N; Mapp S; Susman R; Morgan S; Cooney J; Currie M; Popat U; Bochtler T; Izraeli S; Bradstock K; Godley LA; Krämer A; Fröhling S; Wei AH; Forsyth C; Mar Fan H; Poplawski NK; Hahn CN; Scott HS
    Blood Adv; 2020 Mar; 4(6):1131-1144. PubMed ID: 32208489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloid neoplasms with germ line RUNX1 mutation.
    Hayashi Y; Harada Y; Huang G; Harada H
    Int J Hematol; 2017 Aug; 106(2):183-188. PubMed ID: 28534116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Familial platelet disorder due to germline exonic deletions in
    Engvall M; Karlsson Y; Kuchinskaya E; Jörnegren Å; Mathot L; Pandzic T; Palle J; Ljungström V; Cavelier L; Hellström Lindberg E; Cammenga J; Baliakas P
    Leuk Lymphoma; 2022 Oct; 63(10):2311-2320. PubMed ID: 35533071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation.
    Krutein MC; Hart MR; Anderson DJ; Jeffery J; Kotini AG; Dai J; Chien S; DelPriore M; Borst S; Maguire JA; French DL; Gadue P; Papapetrou EP; Keel SB; Becker PS; Horwitz MS
    Blood Adv; 2021 Feb; 5(3):687-699. PubMed ID: 33560381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered platelet-megakaryocyte endocytosis and trafficking of albumin and fibrinogen in RUNX1 haplodeficiency.
    Del Carpio-Cano F; Mao G; Goldfinger LE; Wurtzel J; Guan L; Alam MA; Lee K; Poncz M; Rao AK
    Blood Adv; 2024 Apr; 8(7):1699-1714. PubMed ID: 38330198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A role for Rab27b in NF-E2-dependent pathways of platelet formation.
    Tiwari S; Italiano JE; Barral DC; Mules EH; Novak EK; Swank RT; Seabra MC; Shivdasani RA
    Blood; 2003 Dec; 102(12):3970-9. PubMed ID: 12907454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole-exome sequencing confirmation of a novel heterozygous mutation in RUNX1 in a pregnant woman with platelet disorder.
    Obata M; Tsutsumi S; Makino S; Takahashi K; Watanabe N; Yoshida T; Tamiya G; Kurachi H
    Platelets; 2015; 26(4):364-9. PubMed ID: 24853048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM).
    Schlegelberger B; Heller PG
    Semin Hematol; 2017 Apr; 54(2):75-80. PubMed ID: 28637620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
    Mill CP; Fiskus WC; DiNardo CD; Reville P; Davis JA; Birdwell CE; Das K; Hou H; Takahashi K; Flores L; Ruan X; Su X; Loghavi S; Khoury JD; Bhalla KN
    Blood Cancer J; 2024 Feb; 14(1):25. PubMed ID: 38316746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.